Takeda expands Latin America footprint with new subsidiary in Ecuador
Japan’s largest drugmaker Takeda Pharmaceuticals (TYO: 4502) says it is expanding its presence in Latin America with the launch of its wholly-owned subsidiary in Ecuador, Takeda Ecuador SA, which be headquartered in Quito and will be responsible for the sales and marketing of Takeda’s products in Ecuador.
Takeda is building a leading position in Latin America. It says it has a direct presence in Brazil, Mexico, Argentina, Venezuela, Colombia and Ecuador, and is looking at opportunities to further expand its footprint in the region. According to IMS Health, pharmaceutical sales in Latin America totaled $74.5 billion in 2012 and are expected to grow at a compound annual rate of 8% between 2012 and 2016. Takeda plans to outgrow the market over the same period.
Dynamic Ecuador market
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze